Investment Rating - The investment rating for the company is "Buy (Maintain)" [2] Core Views - The company's H1 2024 performance met expectations, with revenue of 839 million yuan, a year-on-year increase of 17.75%, and a net profit attributable to shareholders of 121 million yuan, up 20.88% year-on-year [4] - The company is experiencing a recovery in demand, leading to an increase in market share for carrier tapes and adhesive tapes, while the release of new products in the release film segment is progressing smoothly [5] - The company has successfully developed low roughness release films for MLCC and mid-to-high-end polarizer release films, with stable supply to major customers [5] Financial Performance Summary - In H1 2024, the company achieved a gross profit margin of 36.52%, an increase of 3.32 percentage points year-on-year, and a net profit margin of 14.45%, up 0.38 percentage points year-on-year [4] - The company’s revenue for H1 2024 was 839 million yuan, with a net profit of 121 million yuan, and a net profit after deducting non-recurring gains and losses of 118 million yuan [4] - The company expects revenues of 2.112 billion yuan, 2.874 billion yuan, and 3.789 billion yuan for 2024, 2025, and 2026 respectively, with net profits of 364 million yuan, 515 million yuan, and 696 million yuan for the same years [5][6] Business Segment Performance - In H1 2024, revenue from carrier tapes was 599 million yuan (up 14.50% YoY), adhesive tapes revenue was 126 million yuan (up 29.61% YoY), and film materials revenue was 71.74 million yuan (up 18.41% YoY) [5] - The company has maintained a high market share in the paper carrier tape sector and is actively expanding capacity in the adhesive tape sector [5] - The company has developed its own production capabilities for precision molds and raw materials in the plastic carrier tape sector, further enhancing its production capacity [5]

[Table_Main] 证券研究报告 | 公司点评 迎驾贡酒(603198.SH) 2024 年 08 月 17 日 增持（维持） 所属行业：食品饮料/白酒Ⅱ 当前价格(元)：50.72 证券分析师 熊鹏 资格编号：S0120522120002 邮箱：xiongpeng＠tebon.com.cn 尤诗超 资格编号：S0120524070004 邮箱：yousc3＠tebon.com.cn 研究助理 市场表现 迎驾贡酒 沪深300 -34% -26% -17% -9% 0% 9% 17% 2023-08 2023-12 2024-04 | --- | --- | --- | --- | |-------------|--------|--------|--------| | 沪深300对比 | 1M | 2M | 3M | | 绝对涨幅(%) | -10.80 | -17.49 | -29.63 | | 相对涨幅(%) | -6.43 | -11.96 | -21.54 | 资料来源：德邦研究所，聚源数据 相关研究 1.《迎驾贡酒（603198.SH）：洞藏延 续高增，业绩超预期》，2024.4.26 2.《 ...

[Table_Main] 证券研究报告 | 公司点评 金徽股份(603132.SH) 2024 年 08 月 17 日 相关研究 | --- | --- | |--------------------------------------------------------|--------------------------------| | 金徽股份（ 增持（维持） | 603132.SH ）： 24H1 | | 所属行业：有色金属 / 工业金属 当前价格 ( 元 ) ： 11.38 | 铅锌矿量价齐升，净利增超 40% | 投资要点 证券分析师 翟堃 资格编号：s0120523050002 邮箱：zhaikun＠tebon.com.cn 研究助理 谷瑜 邮箱：guyu5＠tebon.com.cn 市场表现 -23% -11% 0% 11% 23% 34% 金徽股份 沪深300 | --- | --- | --- | --- | |----------------------------------|----------------|--------------|--------| | -34% 2023- ...

[Table_Main] 证券研究报告 | 公司点评 青矩技术(836208.BJ) 2024 年 08 月 17 日 投资要点 | --- | --- | |-------------------------------------------------------------|----------------------------------------| | 增持（维持） 青矩技术（ | ）： 24Q2 固投降速导致 | | | | | | | | 所属行业：建筑装饰 / 工程咨询服务Ⅱ 当前价格 ( 元 ) ： 20.27 | 需求偏弱，经营重心转为攻坚核心战略客户 | | | | 证券分析师 闫广 资格编号：S0120521060002 邮箱：yanguang＠tebon.com.cn 王逸枫 资格编号：S0120524010004 邮箱：wangyf6＠tebon.com.cn 研究助理 市场表现 0% 17% 34% 51% 69% 青矩技术 沪深300 -17% | --- | --- | --- | --- | |--------------------------------|---- ...

[Table_Main] 证券研究报告 | 公司点评 孩子王(301078.SZ) 2024 年 08 月 16 日 增持（维持） 所属行业：商贸零售/专业连锁Ⅱ 当前价格(元)：5.32 证券分析师 易丁依 资格编号：S0120523070004 邮箱：yidy＠tebon.com.cn 研究助理 市场表现 -57% -46% -34% -23% -11% 0% 11% 2023-08 2023-12 2024-04 2024-08 孩子王 沪深300 | --- | --- | --- | --- | |--------------------------------|-------|-------|--------| | | | | | | 沪深 300 对比 | 1M | 2M | 3M | | 绝对涨幅 (%) | -1.66 | -3.38 | -14.73 | | 相对涨幅 (%) | 2.09 | 2.15 | -6.99 | | 资料来源：德邦研究所，聚源数据 | | | | 相关研究 1.《孩子王（301078.SZ）：Q2 业绩环 比改善，看好全国化优势沉淀》， 2023.8.29 孩子 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][6]. Core Views - The company reported a revenue of 5.36 billion yuan in Q2 2024, representing a year-on-year increase of 22.6% and a quarter-on-quarter increase of 53.7%. However, the net profit attributable to the parent company was -1.2 billion yuan, indicating a slight increase in losses compared to the previous year [5]. - The gross margin for Q2 2024 was 2.8%, an increase of 8.0 percentage points year-on-year and 4.1 percentage points quarter-on-quarter [5]. - The company is expected to see significant sales growth in Q3 2024, with over 28,000 new orders in July and plans to launch new models at the Paris Auto Show in October 2024 [5]. - The international expansion is progressing steadily, with nearly 2,000 units of C10 and T03 shipped to Europe, and plans to establish over 200 sales outlets in Europe by the end of 2024 [5]. Financial Summary - Revenue projections for 2024, 2025, and 2026 are 27.49 billion yuan, 47.22 billion yuan, and 68.28 billion yuan, respectively. The corresponding net profits are expected to be -4.18 billion yuan, -2.56 billion yuan, and 130 million yuan [6][8]. - The gross margin is projected to improve to 5.5% in 2024, 9.0% in 2025, and 11.5% in 2026 [8]. - The company’s total assets are estimated to reach 30.23 billion yuan in 2024, with a projected total market value of 30.28 billion yuan [7][8].

[Table_Main] 证券研究报告 | 行业月报 煤炭开采 2024 年 08 月 16 日 煤炭 优于大市（维持） 证券分析师 翟堃 资格编号：s0120523050002 邮箱：zhaikun＠tebon.com.cn 薛磊 资格编号：S0120524020001 邮箱：xuelei＠tebon.com.cn 研究助理 谢佶圆 邮箱：xiejy＠tebon.com.cn 市场表现 煤炭开采 沪深300 -22% -11% 0% 11% 22% 33% 44% 55% 2023-08 2023-12 2024-04 资料来源：聚源数据，德邦研究所 相关研究 1.《煤炭周报：基本面震荡磨底,建议 逢低布局》，2024.8.11 2.《永泰能源事件点评：资源规模扩 张，业绩增长可期》，2024.8.8 3.《煤炭周报：日耗延续高位，板块 调整后价值凸显》，2024.8.4 4.《新集能源（601918.SH）：吨煤 毛利同比高增，煤电一体未来可期》， 2024.7.31 5.《平煤股份事件点评：煤炭生产恢 复，增持彰显信心》，2024.7.31 煤炭行业月报：供给增速放缓， 需求预期改善 [Table_Su ...

Investment Rating - Buy (Maintained) [1] Core Views - The company reported robust performance in H1 2024, with revenue reaching 2.15 billion yuan (+11.02% YoY) and net profit attributable to shareholders of 402 million yuan (+27.28% YoY) [1] - The finished drug business showed strong growth, with revenue increasing by 17.13% YoY to 1.301 billion yuan, driven by sales system upgrades [1] - The company's marketing reform has begun to show results, with rapid growth in out-of-hospital market revenue, which increased by over 80% YoY in H1 2024 [2] - The company's first Class 1 new drug, Jinonning® (Didaxinib Capsules), officially entered the market in March 2024, marking a new stage of "innovation and imitation combination" for the company [2] - The company is expected to achieve net profits of 722 million yuan, 822 million yuan, and 941 million yuan in 2024, 2025, and 2026, respectively, with corresponding PE valuations of 13.6x, 12.0x, and 10.5x [2] Financial Performance - In H1 2024, the company's revenue from finished drugs was 1.301 billion yuan (+17.13% YoY), while revenue from APIs was 501 million yuan (+5.66% YoY), and revenue from medical devices was 312 million yuan (+0.46% YoY) [1] - The company's sales expenses decreased by 3.63% YoY in H1 2024, with a sales expense ratio of 17.85% (-2.72 percentage points) [2] - The company's gross margin is expected to improve from 50.6% in 2023 to 53.5% in 2026, with net profit margins increasing from 15.6% to 16.7% over the same period [4] - The company's ROE is projected to rise from 11.2% in 2023 to 13.0% in 2026, reflecting improved profitability [4] Business Development - The company has shifted its marketing model from a "line-based" system to a hospital and retail division model, focusing on deepening hospital market penetration and expanding the out-of-hospital market [2] - The company has established strategic partnerships with multiple chain pharmacies, accelerating the layout of its retail business [2] - The company's R&D pipeline is progressing steadily, with several projects in clinical trials, including JX11502MA Capsules and Kangfuxin Enteric-coated Capsules II [2] Valuation and Forecast - The company's revenue is expected to grow from 3.999 billion yuan in 2023 to 5.688 billion yuan in 2026, with a CAGR of 12.4% [4] - The company's net profit is forecasted to increase from 619 million yuan in 2023 to 941 million yuan in 2026, with a CAGR of 14.9% [4] - The company's EPS is projected to rise from 0.72 yuan in 2023 to 1.09 yuan in 2026, with a P/E ratio decreasing from 17.67x to 10.5x over the same period [4]

买入（首次） 所属行业：美容护理/化妆品 当前价格(元)：22.91 证券分析师 易丁依 资格编号：S0120523070004 邮箱：yidy＠tebon.com.cn 市场表现 -26% -17% -9% 0% 9% 17% 2023-08 2023-12 2024-04 2024-08 丸美股份 沪深300 | --- | --- | --- | --- | |--------------------------------|--------|--------|--------| | | | | | | | | | | | 沪深 300 对比 | 1M | 2M | 3M | | 绝对涨幅 (%) | -10.47 | -22.86 | -27.07 | | 相对涨幅 (%) | -6.72 | -17.23 | -18.46 | | 资料来源：德邦研究所，聚源数据 | | | | 相关研究 丸美股份：电商转型展现成效， 打造彩妆第二曲线 单击或点击此处输入文字。 投资要点 导语：丸美股份通过调整团队架构+线下转电商渠道+内部高研发投入打造自研原 料，实现基本面边际拐点，业绩自 22Q3 触底后逐步回升 ...

[Table_Main] 证券研究报告 | 公司点评 重庆啤酒(600132.SH) 2024 年 08 月 16 日 买入（维持） 所属行业：食品饮料/非白酒 当前价格(元)：59.38 证券分析师 熊鹏 资格编号：S0120522120002 邮箱：xiongpeng＠tebon.com.cn 韦香怡 资格编号：S0120522080002 邮箱：weixy＠tebon.com.cn 研究助理 市场表现 重庆啤酒 沪深300 -43% -34% -26% -17% -9% 0% 9% 17% 2023-08 2023-12 2024-04 2024-08 | --- | --- | --- | --- | |-------------|-------|-------|--------| | 沪深300对比 | 1M | 2M | 3M | | 绝对涨幅(%) | -5.49 | -9.74 | -17.98 | | 相对涨幅(%) | -1.73 | -4.11 | -9.36 | 资料来源：德邦研究所，聚源数据 相关研究 1.《Q4 业绩略低预期，高分红提振信 心-重庆啤酒（600132.SH）：Q4 ...